ClinicalTrials.gg
CompletedNCT00613691Updated Oct 21, 2013

A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma

A Phase 1 interventional study of SPI-1620 in Carcinoma, sponsored by Spectrum Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-21.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 402 studies in Carcinoma with a site in United States — 70 open to participants now, 112 under way, 19 of them phase 3. Carcinoma · United States.

Enrollment
216th of 358
36 · median 48
Started
2008
with 20 others
Phase 1
111 of 402
14 open now
Registered
75th of 402
by date

Among the 402 studies in Carcinoma with a site in United States, this one is the 216th largest by enrollment of the 358 interventional ones that give a count, is one of 21 that started in 2008, is one of 111 in phase 1, and was the 75th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

70 of the 402 studies in Carcinoma with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a 2-part, open-label, single-arm, dose escalation study. Part I will define the Maximum Tolerated Dose (MTD) and optimal dose of SPI-1620 and evaluate its PK and PD properties. Once the MTD for SPI-1620 is identified, a second phase of the study will focus on dose escalation of docetaxel studied in groups of 3-6 patients. This part of the study will assess the safety and tolerability of increasing doses of docetaxel administered with the optimal dose of SPI 1620 defined in Part I.

Read the detailed description

This is a 2-part, open-label, single-arm, dose escalation study. Part I will define the Maximum Tolerated Dose (MTD) and optimal dose of SPI-1620 and evaluate its PK and PD properties. Eligible patients will receive SPI-1620 delivered intravenously over one minute on Days 1, 8 and 15. On Day 8 patients will undergo a series of four H215O PET Blood Flow (BF) scans which will be used to assess alterations in BF induced by SPI-1620 in tumor and non-tumor ROIs (Region of Interest). Fifteen minutes after receiving SPI-1620 on Day 15, patients will receive docetaxel, 60 mg/m2, administered by infusion over 1 hour. Accelerated dose escalation of SPI-1620 will be employed: one patient will be treated at each dose level with 100% increases between dose levels. If any grade 2 or higher, related AE occurs, the trial will revert to 3-patient cohorts with 40% dose escalation between groups. There will be no intrapatient dose escalation. Dose escalation will continue until there is either no further increase in tumor blood flow as assessed by H215O PET scan, or until significant toxicity is observed. Once the MTD for SPI-1620 is identified, a second phase of the study will focus on dose escalation of docetaxel studied in groups of 3-6 patients. This part of the study will assess the safety and tolerability of increasing doses of docetaxel administered with the optimal dose of SPI 1620 defined in Part I. If 60 mg/m 2 was tolerated in Part I then up to six patients in Part II will receive docetaxel at a dose of 80 mg/m2 once every 3 weeks. If this is tolerated the next group of patients will receive docetaxel 100 mg/m2 once every 3 weeks.

03

Conditions studied

  • Carcinoma

Browse trials for

Keywords

  • Refractory
  • Progressive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All of the following inclusion criteria must be met prior to participation in this study

  1. The patient must sign an . A signed consent form is required prior to the performance of any protocol-related procedures or assessments.
  2. The patient must be >= 18 years of age.
  3. The patient must have progressive or recurrent carcinoma and has failed all standard therapies for his/her tumor.
  4. The patient must have a negative CT scan with contrast of the brain or MRI of the brain within 45 days of enrollment.
  5. The patient must be using an acceptable/effective method of if she is a female patient of .
  6. The patient must have a negative serum pregnancy test within 14 days of entering the protocol if she is a female of childbearing potential.
  7. The patient must have an score \<= 2.
  8. The patient must be willing and able to abide by the protocol.

Exclusion criteria

Exclusion Criteria:

None of the exclusion criteria may be met prior to patient participation in this study

  1. The patient has a history of CHF, migraines, coagulopathy, stroke or inadequately controlled hypertension.
  2. The patient has asthma or symptomatic .
  3. The patient has autonomic nerve dysregulation syndrome.
  4. The patient has angina or is taking nitrates or has had a MI within the past six months.
  5. The patient has a significant ventricular arrhythmia, class III or IV CHF or has a known coronary stenoses >80% and has not undergone either angioplasty or CABG
  6. The patient is taking phosphodiesterase inhibitors
  7. The patient has malignant or poorly controlled hypertension (>160/100)
  8. The patient has symptomatic orthostatic hypotension
  9. The patient is taking arterial vasodilators such as nifedipine or amlodipine or alpha blockers such as terazosin, tamsulosin and prazosin.
  10. The patient has a screening less than 1.5 K/uL
  11. The patient has a screening count less than 100 K/uL.
  12. The patient has a screening creatinine greater than 2.0 mg/dL
  13. The patient has a screening amino alanine transferase (), or aspartate aminotransferase (AST) > 2.5 times the upper limit of the laboratory reference range or a total > 1.0 mg/dL.
  14. The patient has a known immunodeficiency disorder.
  15. The patient is enrolled, or the patient plans to enroll, in any concurrent study of another product.
  16. The patient is taking, or the patient is planning to take other cancer treatments during the study except for patients with prostate cancer using LHRH agonist therapy.
  17. The patient has a known to any of the components of SPI 1620 or to docetaxel.
  18. The patient has previously failed treatment with docetaxel for his/her tumor and a dose of SPI-1620 that has been shown to enhance tumor blood flow has not been identified.
  19. The patient does not have a tumor that is at least 1cm. -
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    SPI-1620

    SPI-1620 an endothelin B agonist

    Drug: SPI-1620

Interventions

  • SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of SPI-1620 administered to patients with recurrent or progressive carcinoma who have failed all standard therapy.

    Time frame: every three weeks

Secondary outcomes

  1. To assess the pharmacokinetic and pharmacodynamic profiles of SPI-1620 administered to patients with recurrent or progressive carcinoma who have failed all standard therapy.

    Time frame: one week

  2. To identify the optimum dose of SPI-1620 to be used in future Phase II studies.

    Time frame: every three weeks

  3. To assess the safety and tolerability of doses of docetaxel from 60 mg/m2 to 100 mg/m2 when given following infusion of SPI 1620.

    Time frame: every three weeks

07

Study locations

1 site
  • START
    San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jan 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2008
First posted
Feb 13, 2008
Start
Jan 2008
Primary completionActual
Jan 2012
CompletionActual
Dec 2012
Last update
Oct 21, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00613691
Responsible party
Sponsor
First posted
Feb 13, 2008
Start date
Jan 2008
Primary completion
Jan 2012
Completion
Dec 2012
Last update
Oct 21, 2013

Study contacts

Anthony Tolcher, MD
principal investigator · START

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovateltide

Start the discussion